Drug Discovery World

FEBRUARY 2, 2023

This therapy targets the ESR1 mutations in metastatic breast cancer and provides patients with a convenient oral once-daily dose.” The post FDA-approved therapy targets ESR1 mutations in breast cancer appeared first on Drug Discovery World (DDW).

FDA Approval 130

FDA Approval FDA Therapies Medical Schools 130

Drug Discovery World

JULY 5, 2024

Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD). ” Amgen is now planning to file for approval in the US following results on the MITIGATE study. .

Treatment 147

Treatment Medical Schools Trials Clinical Trials 147

Drug Discovery World

APRIL 16, 2023

Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from a Phase III trial. According to the results of an interim analysis conducted after a median follow-up of 17.4

Therapies 130

Therapies Medical Schools Trials Treatment 130

Drug Discovery World

FEBRUARY 15, 2024

With more than a dozen active programmes, Alys anticipates further organic pipeline growth from its cutting-edge platforms, covering inflammatory diseases, autoimmune diseases, dermatology supportive care for cancer patients and rare dermatoses.

Medical Schools 130

Medical Schools Pharmaceuticals Laboratories Disease 130

Drug Discovery World

OCTOBER 13, 2023

Researchers at Harvard Medical School (HMS) in the US and the University of Oxford have developed a new artificial intelligence (AI) tool named EVEscape that can predict new viral variants before they emerge. According to the European Centre for Prevention and Disease Control, the current variants of interest are Omicron variants BA.2.75,

Vaccine 264

Vaccine Virus Medical Schools Immune Response 264

Broad Institute

APRIL 2, 2024

Scientists link certain gut bacteria to lower heart disease risk By Allessandra DiCorato April 2, 2024 Breadcrumb Home Scientists link certain gut bacteria to lower heart disease risk Study finds several species of cholesterol-metabolizing bacteria in people with lower cholesterol levels.

Disease 145

Disease Medical Schools Hospitals DNA 145

Drug Discovery World

SEPTEMBER 3, 2024

Semaglutide has been found to reduce the rates of all-cause death, including as a result of Covid-19, in those who are overweight or have obesity and established cardiovascular disease without diabetes. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

Medical Schools 147

Medical Schools Trials Disease Hospitals 147

Broad Institute

AUGUST 7, 2024

At the Broad, he directs the Cancer Genome Computational Analysis Group , and he is a professor of pathology at Harvard Medical School and director of bioinformatics at Massachusetts General Hospital. Anna Greka ’s research focuses on fundamental mechanisms of cellular dysfunction in genetic diseases with a focus on membrane proteins.

Medical Schools 90

Medical Schools Hospitals Bioinformatics Vaccine 90

Drug Target Review

AUGUST 29, 2024

What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

biobide

FEBRUARY 2, 2024

Pediatric cancers exhibit differences at the genetic level compared to the same form of adult disease, which may influence the selected treatment. Children and adolescents lack robust preclinical models to replicate the pathologies and provide precise and targeted therapies.

Disease 59

Disease Medical Schools Pharma Companies Clinical Trials 59

Broad Institute

JANUARY 25, 2024

They found significant associations between the thinning of different retinal layers and increased risk of developing ocular, cardiac, pulmonary, metabolic, and neuropsychiatric diseases and identified genes that are associated with retinal layer thickness. Their findings are published in Science Translational Medicine. “We

Disease 124

Disease Research Medical Schools Science 124

The Pharma Data

DECEMBER 5, 2020

5, 2020 — A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Lewis Hsu, chief medical officer of the Sickle Cell Disease Association of America. SATURDAY, Dec.

Therapies 52

Therapies Disease Medical Schools Virus 52

Drug Discovery World

JULY 3, 2023

Janssen has announced positive results from the proof-of-concept Phase II UNITY trial for the treatment of pregnant individuals at high risk of early-onset severe (EOS) haemolytic disease of the foetus and newborn (HDFN).

Trials 130

Trials Medical Schools Clinical Development Treatment 130

Drug Discovery World

JANUARY 9, 2023

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity. . This dual-action cell therapy was safe, applicable, and efficacious in these models. .

Medical Schools 130

Medical Schools Engineering Vaccine Therapies 130

The Pharma Data

JANUARY 25, 2021

25, 2021 — Recommendations are presented for the diagnosis and management of von Willebrand disease (VWD) in two clinical guidelines issued by the American Society of Hematology, International Society on Thrombosis and Haemostasis, National Hemophilia Foundation, and World Federation of Hemophilia and published online Jan. MONDAY, Jan.

Disease 52

Disease Medical Schools Laboratories Therapies 52

Drug Target Review

APRIL 26, 2023

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs.

RNA 98

RNA Medical Schools Engineering DNA 98

Drug Target Review

FEBRUARY 29, 2024

During my academic career, I had the opportunity to examine the underlying causes of neurodegenerative diseases like Parkinson’s disease and develop novel animal models to investigate potential disease-modifying therapeutics. AskBio) I continue to work to bring innovative gene therapies to patients in need.

Therapies 111

Therapies Disease Clinical Trials Science 111

The Pharma Data

APRIL 22, 2023

Multiple sclerosis (MS) is a devastating autoimmune disease that destroys the protective myelin covering around nerves, disrupting communication between the brain and body, and causing patients’ ability to move and function to progressively decline. million individuals that currently have to live with the disease.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

Broad Institute

MARCH 8, 2024

“Type 2 diabetes is a disease of elevated blood sugar impacting approximately one in 10 people in the United States that can cause devastating health complications and is usually not cured. Udler and her colleagues assessed genetic findings from more than 1.4 Adapted from an MGH press release. Paper cited: Smith K, Deutsch AJ, McGrail C.,

Medical Schools 127

Medical Schools Hospitals Disease Therapies 127

Broad Institute

AUGUST 19, 2024

This study is an important example of how understanding core metabolic requirements and functions of key bacteria can lead directly to new therapies that allow us to modify the microbiome for improved health,” said co-senior author Seth Bloom, an infectious diseases instructor at the Massachusetts General Hospital.

Hospitals 121

Hospitals Medical Schools Treatment Science 121

The Pharma Data

JUNE 25, 2021

First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting. 41.5), KEYTRUDA demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; KENILWORTH, N.J.–(BUSINESS

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

JUNE 2, 2022

Novartis today announced a partnership with the American Society of Hematology (ASH) to provide six additional African nations with technology that is already being used in Ghana to document and share the diagnosis of babies with sickle cell disease.

Disease 52

Disease Medical Schools Treatment Therapies 52

Drug Discovery World

APRIL 16, 2023

The randomised KEYNOTE-942 trial assessed the efficacy of mRNA-4157/V940 in prolonging RFS in patients with resected, stages IIIB/IIIC/IIID and IV melanoma when given in combination with pembrolizumab, the standard-of-care adjuvant therapy in this patient population. in the combination arm and 62.2%

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Target Review

MAY 16, 2024

The body’s ability to maintain homeostasis in chronic inflammatory and autoimmune diseases is a defining feature of good health, and a goal is largely neglected by modern medicine. This suggests that the field of drug discovery is primed for a paradigm shift in the fundamental strategy of how diseases are treated.

Disease 64

Disease Medical Schools Therapies Treatment 64

Nvidia Developer: Drug Discovery

JULY 14, 2022

Drug discovery startup Insilico Medicine—alongside researchers from Harvard Medical School, Johns Hopkins School of Medicine, the Mayo Clinic, and. ALS is a debilitating disease. Today, patients typically face an average life expectancy of between two and five years after symptom onset. This is only the beginning.”

Medical Schools 52

Medical Schools Clinical Trials Engineering FDA Approval 52

The Pharma Data

JUNE 2, 2023

Zouboulis, President of the European Hidradenitis Suppurativa Foundation, Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, and Founding Professor of Dermatology and Venereology at the Brandenburg Medical School, Germany.

Medical Schools 52

Medical Schools Treatment Disease Therapies 52

Drug Discovery World

JULY 29, 2022

From immunity to metabolism to mental health, it seems like the gut microbiome has been linked to every aspect of human health and disease. muciniphila’s ability to manipulate the immune system and fight disease. Study after study had suggested that A. Until the current work, though, no one could confirm the connection by showing how.

Research 130

Research Immune Response Medical Schools Disease 130

Broad Institute

NOVEMBER 13, 2023

The initial focus of the Gerstner Center is to develop an ultrasensitive liquid biopsy test to detect minimal residual disease (MRD) — the presence of tumor cells in the body after treatment. Doing so would guide treatment decisions, such as whether to continue therapy. "We

DNA 116

DNA Medical Schools Treatment Therapies 116

Drug Target Review

DECEMBER 28, 2023

In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. However, if the therapy targets only the subclonal (branch) mutations, this will result in the mere ‘pruning’ of specific branches rather than elimination of the whole cancer.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Drug Discovery World

MAY 9, 2024

DDW Editor Reece Armstrong speaks to Michael Wyand, Chief Executive Officer/Director, Oxeia Biopharmaceuticals about the development of the company’s treatment for concussion (OXE103) and the current lack of effective therapies for brain injuries.

Therapies 182

Therapies Medical Schools Trials FDA Approval 182

Drug Target Review

FEBRUARY 26, 2024

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59

Broad Institute

JULY 26, 2022

By Stephanie Dutchen, Harvard Medical School Office of Communications and External Relations July 26, 2022 Credit: Susanna Hamilton, Broad Communications From immunity to metabolism to mental health, it seems like the gut microbiome has been linked to every aspect of human health and disease. muciniphila ’s cell membrane.

Research 52

Research Immune Response Medical Schools Disease 52

The Pharma Data

SEPTEMBER 18, 2020

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi and Regeneron’s jointly-developed PD-1 inhibitor Libtayo (cemiplimab) in the treatment of locally advanced basal cell carcinoma (BCC) in patients for whom hedgehog inhibitor (HHI) therapy is not applicable.

Medical Schools 52

Medical Schools Trials Hospitals Therapies 52

The Pharma Data

JANUARY 17, 2021

Optometrists provide comprehensive eye care, including evaluations for glasses and contact lenses and common eye diseases. Ophthalmologists are physicians who have completed four years of medical school and four years of residency training. They can also treat acute eye problems such as pink eye or sties.

Medical Schools 52

Medical Schools Doctors Treatment Disease 52

The Pharma Data

MAY 15, 2023

For people living with HDV with advanced disease progression, including cirrhosis, mortality rates can be as high as 50% within five years, presenting significant disease burden and high healthcare-related costs. bulevirtide was granted Breakthrough Therapy and Orphan Drug designations by the Food and Drug Administration (FDA).

Virus 40

Virus Marketing Treatment Medical Schools 40

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

On Medicine

APRIL 6, 2023

I have a background in Biomedical Engineering prior to medical school and a particular interest in global health and healthcare in resource-limited settings. The chronic cardiovascular diseases are frequently insidious but pervasive and progressive, and early subclinical changes are difficult to identify in children.

Medical Schools 52

Medical Schools Hospitals International Treatment 52